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Summary 
THIRTY-one patients with histologically diagnosed chronic active hepatitis were followed 
clinically, biochemically and histologically for a mean of 32.5 months. Nineteen patients were 
intravenous drug abusers. Eighteen patients showed histological improvement: of these 14 
had hepatitis B virus (HBV) associated disease. Thirteen patients were unchanged or worse on 
repeat biopsy; 5 of these had HBV associated disease. The results of this study suggest that 
HBV associated chronic active hepatitis is a less severe disease with a better prognosis than 
non HBV disease. 
Introduction 
 Chronic active hepatitis was traditionally believed to be a disease with a poor 
prognosis, and if untreated a life expectancy of about 5 years (MacKay and Wood, 1962; 
Bearn, Knuckel and Slater, 1956). Subsequent work proved this to be untrue of hepatitis B 
virus (HBV) associated chronic active hepatitis which was found to have a better prognosis 
(Sherlock, 1974). In this study, we report the clinical, biochemical and histological prognosis 
in 31 patients with chronic active hepatitis followed for between 6 and 84 months. 
Patients and Methods 
 Patients were selected for inclusion in this study on the basis of a histological diagnosis 
of chronic active hepatitis and having had at least one biopsy 6 or more months following the 
initial biopsy. There were 19 drug abusing patients who were referred from the Drug 
Advisory and Treatment Centre, and 12 non drug abusing patients who were attending the 
Department of Medicine and Gastroenterology. 
 Each patient was examined for stigmata of chronic liver disease and in drug abusing 
patients stigmata of such abuse was sought. 
 Each patient had blood taken for estimation of haemoglobin, white cell count, platelet 
count, prothrombin time, serum aspartate, transaminase (SGPT) alkaline phosphatase, 
bilirubin, total serum proteins, serum albumin, immunoglobulins, IgG, IgA, IgM, anti-nuclear 
factor, anti-mitochondrial antibody and smooth muscle antibody. The presence of hepatitis B 
surface antigen (HBsAg) and antibody (anti HBs was sought. 
 Liver biopsy was performed following informed consent. Histological diagnosis was 
made according to the criteria suggested in a Review by an International Group (1977) in 
which the classification of DeGroote and his colleagues (1968) was modified and extended. 
Chronic active hepatitis was therefore defined as “a chronic inflammatory and fibrosing lesion 
of the liver, of varied aetiology and varied histological features. The features common to all 
untreated examples are: piecemeal necrosis together with new fibre formation and 
lymphocyte infiltration of the portal tracts and lobules. Other infiltrating cells may be found 
and features of acute hepatitis may be superimposed. Passive septae formed after bridging or 
multilobular liver cell necrosis may be present. Cirrhosis is not a defining criterion, but may 
develop”. 
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 Following diagnosis patients were treated either with prednisolone 10mg daily and 
azothiaprine 50mg daily (Summerskill et al, 1975) or (7 drug abusing patients) sulphasalazine 
1g 3 times daily (Fielding, Arthurs and Doyle, 1982). 
 Patients were reviewed at regular intervals on an out-patient basis and after 6 or more 
months, one or more repeat liver biopsies were performed. Chronic active hepatitis, chronic 
persistent hepatitis and cirrhosis were diagnosed according to the criteria of an International 
Group (1977). Minor changes were said to be present if there was mild swelling of the portal 
tracts with excess cellular infiltrate with or without foci of hepatocellular necrosis. 
Results 
 Thirty-one patients were studied, 22 male and 9 female whose ages ranged from 12 to 
60 (mean 30.5) years. The duration of follow-up was 6 to 84 (mean 32.5) months. Nineteen 
patients were known intravenous drug abusers. Eight patients had a past history of jaundice 
between 6 months and 20 years before diagnosis. Twenty-one patients presented initially with 
jaundice. One had recurrent episodes of jaundice and 2 were never jaundiced. 
 On examination 16 patients had stigmata of chronic liver disease. Ten patients had 
hepatomegaly, one also had splenomegaly. Six patients had palmar erythema, 5 had spider 
naevi, and one had Dupuytren’s contractures. Eighteen drug abusing patients had markings 
compatible with intravenous abuse. 
 Nineteen patients were HBsAg positive and 12 were HBsAg and anti HBs negative 
(Table I). Transaminase levels were normal in only 2 patients at diagnosis and at the end of 12 
months in 8 of 25 patients followed for at least one year. In 4 of the 6 patients followed for 6 
months levels had returned to normal at the end of this time (Tables II and III). Ten patients 
had elevated immunoglobulins (Table IV). Total serum proteins were elevated above 80g/l in 
5 patients. 
 
TABLE I 
Patient group HBsAg Positive HBsAg and anti 
HBs negative 
Drug abusers 
 (9) 
15 4 
Non abusers 
 (12) 
4 8 
TOTAL 19 12 
HBsAg and anti HBs status in patients with CAH. 
 A total of 92 liver biopsies were carried out in these patients. Two patients had 6 
biopsies, 2 and 5, 3 hand 4, 10 had 3 and 14 had 2 biopsies. The histological 
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 TABLE II 
SGPT level 
IU/I 
(N = <45) Diagnosis Twelvemonths 
<45 2 8 
45- 99 2 14 
100- 299 7 2 
300- 499 4 1 
500- 999 3  
1000-3000 7  
SGPT levels at diagnosis and 12 months in 25 patients followed for over a year. 
TABLE III 
SGPT level 
IU/I 
(N = <45) Diagnosis Six months 
<45  4 
45- 99  2 
100- 299   
300- 499 1  
500- 999 1  
1000-3000 4  
SGPT levels in 6 patients followed for 6 months. 
TABLE IV 
Patient group No. with abnormal
immunoglobulins 
IgG 
N= 90-200 IU/ml 
IgM 
(55-285 IU/ml) 
IgA 
(40-315 IU/ml) 
Drug abusers 
(19) 
3 1 3 1 
Non abusers 
(12) 
7 4 3 3 
Abnormal immunoglobulins in drug abusers and non abusers. 
progression is tabulated separately for the HBV positive and HBV negative patients in Tables 
V and VI. 
 Two patients developed jaundice during the course of follow-up and 2 patients 
developed Cushingoid facies; otherwise patients remained clinically well. 
Discussion 
 The evolution of chronic active hepatitis in 31 patients was studied. Nineteen patients 
had HBV associated disease (Table I). It is possible that the drug abusing patients who were 
HBsAg negative may have had chronic liver disease associated with non A and non B viruses 
as these viruses have been implicated as causal agents in chronic liver disease in parenteral 
drug abusers (Rakela and Redeker, 1979). 
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 The non abusing patients without evidence of HBV disease were predominantly 
female, had a higher frequency of abnormality of serum proteins; immunoglobulins, anti-
nuclear factor and smooth muscle antibody were detected more frequently than in the drug 
abusing group. This would suggest that their disease was of the lupoid variety (Doniach et at, 
1966). 
 Of the total group of patients 18 showed an overall histological improvement, 14 of 
these had HBV associated disease. Of the 13 patients who were unchanged or had 
deteriorated on repeat biopsy 5 had HBV associated disease. 
 Traditionally chronic active hepatitis was believed to have a poor prognosis with life 
expectancy of less than 5 years following diagnosis (Mackay and Wood, 1962; Bearn, Knukel 
and Slater, 1956), although these early reports would appear to be related to chronic active 
hepatitis of severe degree only. 
 Chronic active hepatitis associated with HBV is believed to have a better prognosis 
than the lupoid variety in which cirrhosis develops rapidly (Sherlock, 1974). The introduction 
of specific therapy has greatly altered the prognosis. The beneficial effects of steroids in 
chronic active hepatitis has been shown by numerous clinical trials (Cook et al, 1971, 
Soloway et al, 1972; Murray-Lyon et al, 1973; Summerskill et al, 1975). The majority of 
studies comparing the natural history of chronic active hepatitis with and without HBV appear 
to have been related to response to treatment. In 1976 Schalm and his colleagues compared 
the response of severe chronic active hepatitis with and without HBsAg to prednisolone and 
found that HBsAg related disease responded less well. 
 In their study of 74 patients followed for a median period of 45 months Dietrickson and 
Christofferson (1977) concluded that progression is slow and prognosis better in patients with 
HBsAg related disease. The findings in this review would support that claim. 
 A long-term follow-up study of chronic active hepatitis was published in 1978 by 
DeGroote et al. Thirty-five patients,  
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 TABLE V 
Histological evolution in 19 HBV positive patients. 
First biopsy Second biopsy Third biopsy Fourth biopsy  Fifth biopsy Sixth biopsy 
CAH Minor changes Minor changes    
CAH Increased cellular 
activity and 
necrosis 
CAH with early 
cirrhosis 
   
CAH with early 
cirrhosis 
Less activity 
Less fibrosis 
Minor changes  Minor changes   
CAH CAH with less 
infiltrate 
Less necrosis 
    
CAH Less activity CPH    
CAH CAH with 
virrhosis 
Less activity 
    
CAH Less activity     
CAH CAH more 
fibrosis 
CAH less activity    
CAH CAH less 
activity 
    
CAH CAH less 
activity 
    
CAH CAH less activity     
CAH with early 
cirrhosis 
Improved     
CAH CAH less 
activity 
    
CAH with 
cirrhosis 
CAH with 
cirrhosis but 
less hepatocellular 
necrosis 
Unchanged    
CAH with 
Cirrhosis 
Increased 
Cellular 
infiltrate and 
increased 
necrosis 
Unchanged  Further 
Progression 
in severity 
Unchanged No 
improvement 
CAH with early 
cirrhosis 
Increased 
fibrosis 
CAH with 
Established 
cirrhosis 
Unchanged   
CAH with 
cirrhosis 
Persistance of 
Hepatocellular 
necrosis 
CAH with 
cirrhosis and 
fatty 
infiltration 
   
CAH  CAH less 
activity 
    
CAH CAH less 
activity 
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TABLE VI 
Histological evolution in 12 HBV negative patients. 
First biopsy Second biopsy Third biopsy Fourth biopsy  Fifth biopsy Sixth biopsy 
CAH with early 
cirrhosis 
Increased 
cellular 
infiltrate and  
fibrosis 
CAH with 
cirrhosis and  
fatty infiltrate 
Unchanged   
CAH CAH less fibrosis 
Reduced 
Cellularity 
    
CAH with 
cirrhosis 
CAH with 
cirrhosis 
Decreased 
fibrosis but 
persistent 
hepatocellular 
necrosis 
Improved 
minor changes 
Minor changes  
CAH CAH with 
cirrhosis 
Unchanged    
CAH with early 
cirrhosis 
CAH with 
established 
cirrhosis 
Unchanged Unchanged Reduced 
cellularity 
and fibrosis 
Improvement 
maintained 
CAH with early 
cirrhosis 
Less necrosis 
Less cellular 
infiltrate 
Unchanged Further 
reduction 
in activity 
Less cellular 
infiltrate 
Less fibrosis 
 
CAH with 
cirrhosis 
Unchanged     
CAH with early 
cirrhosis and 
fatty infiltration 
Unchanged     
CAH with early 
cirrhosis 
Unchanged     
CAH CAH     
CAH with early 
cirrhosis 
Unchanged Increased 
cellular infiltrate 
More 
hepatocellular 
necrosis 
   
CAH CAH with early 
cirrhosis 
    
17 of whom were HBsAg positive, were followed for up to 15 years (mean 87 months). All 
patients except one were treated with prednisolone and/or azothiaprine. After stopping 
therapy 13 patients relapsed; the majority of relapses were seen in HBsAg positive patients. 
Two-thirds of HBsAg positive patients developed cirrhosis between the second and fifth year 
of evolution compared with less than one-third of the HBsAg negative group. Although the 
patients involved in that study of DeGroote and his colleagues (1978) compare closely with 
those in this review, the results do not. Our HBsAg positive patients had a histologically less 
severe disease with less cirrhosis than the HBsAg negative group. 
 The majority of drug abusing patients in our study who were treated with prednisolone 
and azothiaprine did not comply with therapy. Paradoxically this may have had a beneficial 
effect on the course of their disease, as a recent report suggests that prednisolone used to treat 
HBsAg associated chronic active hepatitis may have a deleterious effect on the course of the 
disease (Lam et at, 1981). 
 Koretz et at (1980) pointed out that the most severe chronic active hepatitis is not 
associated with HBV and that the majority of patients seen by them had a less severe illness 
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which was HBV related. Nevertheless the incidence of cirrhosis among those patients was 
43%, comparable to the 45% initially reported in severely ill patients (Cook et al, 1971). 
 The results of this study would support the concept of HBV associated chronic active 
hepatitis being a less severe disease than non HBV associated chronic active hepatitis; with 
slower progression and a better prognosis. 
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